Jonathan Schelfhout

1.3k total citations · 1 hit paper
64 papers, 806 citations indexed

About

Jonathan Schelfhout is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Emergency Medical Services. According to data from OpenAlex, Jonathan Schelfhout has authored 64 papers receiving a total of 806 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 43 papers in Physiology and 14 papers in Emergency Medical Services. Recurrent topics in Jonathan Schelfhout's work include Respiratory and Cough-Related Research (52 papers), Asthma and respiratory diseases (35 papers) and Pediatric health and respiratory diseases (14 papers). Jonathan Schelfhout is often cited by papers focused on Respiratory and Cough-Related Research (52 papers), Asthma and respiratory diseases (35 papers) and Pediatric health and respiratory diseases (14 papers). Jonathan Schelfhout collaborates with scholars based in United States, United Kingdom and Japan. Jonathan Schelfhout's co-authors include Allison Martin Nguyen, David Muccino, Surinder S. Birring, Carmen La Rosa, Peter V. Dicpinigaitis, Lorcan McGarvey, John A. Smith, Alyn H. Morice, Anjela Tzontcheva and Margaret Vernon and has published in prestigious journals such as The Lancet, Scientific Reports and CHEST Journal.

In The Last Decade

Jonathan Schelfhout

61 papers receiving 789 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

2022 178 citations Lorcan McGarvey, Surinder S. Birring et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Schelfhout United States	16	654	559	227	142	83	64	806
Kristina Biekšienė Lithuania	4	735 1.1×	605 1.1×	200 0.9×	144 1.0×	29 0.3×	8	770
Mirjam J.G. van Manen Netherlands	10	732 1.1×	494 0.9×	133 0.6×	104 0.7×	48 0.6×	14	776
Cécile Lambe France	14	124 0.2×	84 0.2×	55 0.2×	29 0.2×	35 0.4×	55	636
Yewon Kang South Korea	10	145 0.2×	162 0.3×	29 0.1×	15 0.1×	18 0.2×	22	327
Shafik Sidani United States	12	103 0.2×	89 0.2×	9 0.0×	291 2.0×	66 0.8×	17	640
Grace Oscullo Spain	15	436 0.7×	286 0.5×	47 0.2×	5 0.0×	74 0.9×	57	636
Catherine M. Bonuccelli United States	12	506 0.8×	494 0.9×	60 0.3×	5 0.0×	18 0.2×	20	620
G.M. Shaw New Zealand	5	664 1.0×	713 1.3×	28 0.1×	5 0.0×	20 0.2×	22	808
Fehmi Ateş Türkiye	14	90 0.1×	56 0.1×	8 0.0×	250 1.8×	112 1.3×	41	622
P.-O. Stotzer Sweden	8	62 0.1×	163 0.3×	5 0.0×	560 3.9×	61 0.7×	11	730

Countries citing papers authored by Jonathan Schelfhout

Since Specialization

Citations

This map shows the geographic impact of Jonathan Schelfhout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Schelfhout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Schelfhout more than expected).

Fields of papers citing papers by Jonathan Schelfhout

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Schelfhout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Schelfhout. The network helps show where Jonathan Schelfhout may publish in the future.

Co-authorship network of co-authors of Jonathan Schelfhout

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Schelfhout. A scholar is included among the top collaborators of Jonathan Schelfhout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Schelfhout. Jonathan Schelfhout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weiner, Michael, et al.. (2024). Prescriptions of opioid-containing drugs in patients with chronic cough. Therapeutic Advances in Respiratory Disease. 18. 2693838701–2693838701.

Smith, John A., S. Migas, Claire Williams, et al.. (2024). An observational study to understand burden and cost of care in adults diagnosed with refractory chronic cough (RCC) or unexplained chronic cough (UCC). Respiratory Research. 25(1). 265–265. 1 indexed citations

Guilleminault, Laurent, Vicky W. Li, Eileen Fonseca, et al.. (2024). Prevalence and burden of chronic cough in France. ERJ Open Research. 10(2). 806–2023. 8 indexed citations

Chen, Wansu, Michael Schatz, Yichen Zhou, et al.. (2023). Prediction of persistent chronic cough in patients with chronic cough using machine learning. ERJ Open Research. 9(2). 471–2022. 4 indexed citations

Bali, Vishal, Ada Adriano, Aidan Byrne, et al.. (2023). Understanding the economic burden of chronic cough: a systematic literature review. BMC Pulmonary Medicine. 23(1). 416–416. 5 indexed citations

McGarvey, Lorcan, Alyn H. Morice, Ashley Martin, et al.. (2023). Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey. ERJ Open Research. 9(4). 157–2023. 19 indexed citations

Schelfhout, Jonathan, Allison Martin Nguyen, Surinder S. Birring, et al.. (2022). Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough. Lung. 200(6). 717–724. 12 indexed citations

Schelfhout, Jonathan, et al.. (2022). Impact of refractory and unexplained chronic cough on disease burden: a qualitative study. BMC Pulmonary Medicine. 22(1). 372–372. 14 indexed citations

Dicpinigaitis, Peter V., Surinder S. Birring, Michael S. Blaiss, et al.. (2022). Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Annals of Allergy Asthma & Immunology. 130(1). 60–66. 16 indexed citations

10.

Kubo, Takekazu, Kotoba Okuyama, Masashi Kikuchi, et al.. (2021). Disease burden and quality of life of patients with chronic cough in Japan: a population-based cross-sectional survey. BMJ Open Respiratory Research. 8(1). e000764–e000764. 43 indexed citations

11.

Meltzer, Eli O., Robert S. Zeiger, Peter V. Dicpinigaitis, et al.. (2021). Prevalence and Burden of Chronic Cough in the United States. The Journal of Allergy and Clinical Immunology In Practice. 9(11). 4037–4044.e2. 65 indexed citations

12.

Morice, Alyn H., Surinder S. Birring, John A. Smith, et al.. (2021). Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Lung. 199(2). 121–129. 28 indexed citations

13.

Virchow, J. Christian, Vicky W. Li, Eileen Fonseca, et al.. (2021). Chronic cough in Germany: results from a general-population survey. ERJ Open Research. 8(1). 420–2021. 16 indexed citations

14.

Weiner, Michael, Ziyue Liu, Jonathan Schelfhout, et al.. (2020). Specialty Referrals for Cough among Patients with Chronic Cough. Journal of Allergy and Clinical Immunology. 145(2). AB208–AB208. 1 indexed citations

15.

Zeiger, Robert S., Michael Schatz, Qiaowu Li, et al.. (2020). Patient-Reported Burden of Chronic Cough in a Managed Care Organization. The Journal of Allergy and Clinical Immunology In Practice. 9(4). 1624–1637.e10. 27 indexed citations

16.

Weiner, Michael, Paul Dexter, Kim A. Heithoff, et al.. (2020). Identifying and Characterizing a Chronic Cough Cohort Through Electronic Health Records. CHEST Journal. 159(6). 2346–2355. 20 indexed citations

17.

Birring, SS, L. Cardozo, Roger R. Dmochowski, et al.. (2020). A Phase 3b Trial Evaluating the Efficacy of Gefapixant in Reducing Stress Urinary Incontinence in Women with Chronic Cough. A7776–A7776. 1 indexed citations

18.

Ferreira, J., et al.. (2018). PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTING. Value in Health. 21. S225–S226. 3 indexed citations

19.

Brown, Chloë, et al.. (2018). PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: AN ENGLISH PAYER PERSPECTIVE. Value in Health. 21. S451–S452. 3 indexed citations

20.

Kauf, Teresa L., et al.. (2012). Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008. BMC Research Notes. 5(1). 142–142. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact